Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates
Gabriela M. Webb,Kristin A. Sauter,Diana Takahashi,Melissa Kirigiti,Lindsay Bader,Sarah R. Lindsley,Hannah Blomenkamp,Cicely Zaro,Molly Shallman,Casey McGuire,Heather Hofmeister,Uriel Avila,Cleiton Pessoa,Joseph M. Hwang,Allyson McCullen,Matthew Humkey,Jason Reed,Lina Gao,Lee Winchester,Courtney V. Fletcher,Oleg Varlamov,Todd T. Brown,Jonah B. Sacha,Paul Kievit,Charles T. Roberts
DOI: https://doi.org/10.1172/jci.insight.181968
IF: 9.4958
2024-09-25
JCI Insight
Abstract:Current antiretroviral therapy (ART) regimens efficiently limit HIV replication, thereby improving the life expectancy of people living with HIV; however, they also cause metabolic side effects. The ongoing obesity epidemic has resulted in more people with metabolic comorbidities at the time of HIV infection, yet the effect of preexisting metabolic dysregulation on infection sequelae and response to ART is unclear. Here, to investigate the impact of preexisting obesity and insulin resistance on acute infection and subsequent long-term ART, we infected a cohort of lean and obese adult male macaques with SIV and administered ART. The responses of lean and obese macaques to SIV and ART were similar with respect to plasma and cell-associated viral loads, ART drug levels in plasma and tissues, SIV-specific immune responses, adipose tissue and islet morphology, and colon inflammation, with baseline differences between lean and obese groups largely maintained. Both groups exhibited a striking depletion of CD4 + T cells from adipose tissue that did not recover with ART. However, differential responses to SIV and ART were observed for body weight, omental adipocyte size, and the adiponectin/leptin ratio, a marker of cardiometabolic risk. Thus, obesity and insulin resistance had limited effects on multiple responses to acute SIV infection and ART, while several factors that underlie long-term metabolic comorbidities were influenced by prior obesity and insulin resistance. These studies provide the foundation for future investigations into the efficacy of adjunct therapies such as metformin and glucagon-like peptide-1 receptor agonists in the prevention of metabolic comorbidities in people living with HIV.
medicine, research & experimental